dimercaprol has been researched along with Parkinson Disease, Secondary in 2 studies
Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.
dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.
Parkinson Disease, Secondary: Conditions which feature clinical manifestations resembling primary Parkinson disease that are caused by a known or suspected condition. Examples include parkinsonism caused by vascular injury, drugs, trauma, toxin exposure, neoplasms, infections and degenerative or hereditary conditions. Clinical features may include bradykinesia, rigidity, parkinsonian gait, and masked facies. In general, tremor is less prominent in secondary parkinsonism than in the primary form. (From Joynt, Clinical Neurology, 1998, Ch38, pp39-42)
| Excerpt | Relevance | Reference |
|---|---|---|
| "DP reduced acrolein and reversed the upregulation of pain-sensing transient receptor potential ankyrin 1 (TRPA1) channels in the substantia nigra, striatum, and cortex." | 4.02 | Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson's disease: implication of acrolein and TRPA1. ( Chen, Z; Herr, SA; Jiao, Y; Lin, Y; Rogers, E; Shi, L; Shi, R; Tang, J, 2021) |
| "Two cases of myoclonic encephalopathy due to bismuth salts intoxication are reported." | 1.28 | Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters. ( Bermejo, F; Calandre, L; Molina, JA, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shi, L | 1 |
| Lin, Y | 1 |
| Jiao, Y | 1 |
| Herr, SA | 1 |
| Tang, J | 1 |
| Rogers, E | 1 |
| Chen, Z | 1 |
| Shi, R | 1 |
| Molina, JA | 1 |
| Calandre, L | 1 |
| Bermejo, F | 1 |
2 other studies available for dimercaprol and Parkinson Disease, Secondary
| Article | Year |
|---|---|
Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson's disease: implication of acrolein and TRPA1.
Topics: Acrolein; Animals; Behavior, Animal; Cerebral Cortex; Dimercaprol; Dopaminergic Neurons; Hydroxydopa | 2021 |
Myoclonic encephalopathy due to bismuth salts: treatment with dimercaprol and analysis of CSF transmitters.
Topics: Adult; Aged; Dimercaprol; Epilepsies, Myoclonic; Female; Gallic Acid; Humans; Male; Neurotransmitter | 1989 |